Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report
소아 코로나19 환자에서 발생한 항MDA5 소아 피부근염의 치명적 결과: 증례 보고
Case Reports
[키워드] addition
Admission
Anti-MDA5
BAL
BAS
Bronchoalveolar lavage
Case report
children
COVID-19
Cyclophosphamide
dermatomyositis
diagnosed
died
disease
drug
emphysema
health condition
hemophagocytic lymphohistiocytosis
high mortality rate
high risk
hospital
hypoxemic
Hypoxemic respiratory failure
Immunoglobulin
immunosuppressive
immunosuppressive therapy
Infection
initiated
Intensive
Interstitial lung disease
interstitial lung disease (ILD)
intravenous
Intravenous immunoglobulin
juvenile dermatomyositis
Lung disease
MDA5
Methylprednisolone
outcome
Patient
performed
Pneumomediastinum
Pneumothorax
poor prognosis
positive
Real-time PCR
real-time RT-PCR
referred to
Respiratory failure
risk
risk for disease
SARS-CoV-2
SARS-COV-2 infection
secondary hemophagocytic lymphohistiocytosis
Septic shock
severe complications
subcutaneous emphysema
sulfamethoxazole
therapy
Tofacitinib
Treatment
worsening
[DOI] 10.1080/24725625.2020.1832755 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1080/24725625.2020.1832755 PMC 바로가기 [Article Type] Case Reports